Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders
ConditionPreeclampsia
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age18-50
SponsorMayo Clinic
About this trial
The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome.
Eligibility criteria
Qualifiers
Individuals with < 34 0/7 weeks of gestation.
Individuals with severe preeclampsia or HELLP features.
Disqualifiers
Pregnant female patients presenting with disseminated intravascular coagulopathy (DIC).
Individuals with non-reassuring fetal status requiring delivery, non-viable fetuses, previable pregnancy (<23 0/7 weeks gestation), stroke, in utero fetal demise, known atypical hemolytic uremic syndrome, familial or acquired thrombocytopenia purpura, paroxysmal nocturnal hemoglobinuria, allergy to Ravulizumab, inability or unwillingness to sign informed consent.
Trial design
Treatments tested in this trial
- Ravulizumab
Treatment groups
14 Participants
are divided into 1 treatment groupLocations
1Mayo Clinic Minnesota55905, RochesterMinnesota, United States
Sponsors and collaborators
Mayo Clinic
Lead sponsor
Source ClinicalTrials.gov